Drug Details

General Information of the Drug (ID: DR9473)
Name
Amantadine
Synonyms
amantadine; 1-Adamantanamine; 768-94-5; adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Symmetrel; Amantidine; Symadine; Pk-merz; Adamantamine; 1-Adamantamine; Amantadina; Amantadinum; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.3.1.1(3,7)]decan-1-amine; MFCD00074732; CHEMBL660; adamantanylamine; (3s,5s,7s)-Tricyclo[3.3.1.1~3,7~]decan-1-Amine; BF4C9Z1J53; CHEBI:2618; NSC341865; NSC-341865; 768-94-5 (FREE BASE); NCGC00015036-03; Tricyclo[3.3.1.13,7]decan-1-amine; Tricyclo[3.3.1.13,7]decane-1-amine; Amantadine Base; 1-Adamantanamine, 96%; DSSTox_CID_2117; Amantadine [INN:BAN]; DSSTox_RID_76493; Amantadinum [INN-Latin]; DSSTox_GSID_22117; Amantadina [INN-Spanish]; Amant; Amantadine (INN); CAS-768-94-5; NSC83653; 40933-03-7; HSDB 3202; Tricyclo(3.3.1.1(3,7))-decan-1-amine; Tricyclo(3.3.1.1(sup 3.7))decan-1-amine; EINECS 212-201-2; 1-Adamantanamine (8CI); ADAMANTANE,1-AMINO; adamantaneamine; BRN 2204333; adamantyl amine; AmantadineHCl; 1-admantaneamine; 1-Amantadine; Tricyclo(3.3.1.1(sup 3,7))decan-1-amine; 1-adamantanylamine; 1-adamantyl amine; Adamant-1-ylamine; 1-amino-adamantane; adamantane-1-amine; PubChem8733; Mantadine (Salt/Mix); Symmetrel (Salt/Mix); PubChem13903; Spectrum_000030; Tricyclo[3.3.1.1^3,7]decan-1-amine; Prestwick0_000407; Prestwick1_000407; Prestwick2_000407; Prestwick3_000407; Spectrum2_000081; Spectrum3_000291; Spectrum4_000134; Spectrum5_000772; tricyclo[3.3.1.1(3,7)]decan-1-ylamine; tricyclo[3.3.1.1(3,7)]decane-1-amine; 1-Adamantylamine, 97%; Lopac-A-1260; Tricyclo[3.3.1.1(sup3,7)]decan-1-amine; EC 212-201-2; SCHEMBL4098; NCIOpen2_001059; Lopac0_000004; Oprea1_248648; BSPBio_000334; BSPBio_001570; BSPBio_001822; KBioGR_000548; KBioSS_000390; BIDD:GT0757; DivK1c_000815; Exp-105-1 (Salt/Mix); SPBio_000002; SPBio_002273; BPBio1_000368; GTPL4128; SCHEMBL2619248; DTXSID8022117; SCHEMBL15672299; SCHEMBL20409394; SCHEMBL21309814; SCHEMBL21310017; KBio1_000815; KBio2_000390; KBio2_002958; KBio2_005526; KBio3_001322; NINDS_000815; (3R,5S,7s)-Adamantan-1-amine; 1-Adamantamine(1-Aminoadamantane); HMS1791O12; HMS1989O12; HMS3604O07; HMS3887I19; ZINC968256; ACT02873; ALBB-013871; BCP09869; STR04703; Tox21_110068; ANW-43040; BBL004977; BDBM50033369; HTS001826; s5499; SBB071506; STK298781; AKOS000113994; AKOS000119324; AKOS007930692; AKOS015935124; Tox21_110068_1; CCG-204100; CS-W008656; DB00915; MCULE-9686682307; SDCCGSBI-0049993.P005; IDI1_000815; NCGC00015036-01; NCGC00015036-02; NCGC00015036-04; NCGC00015036-05; NCGC00015036-06; NCGC00015036-07; NCGC00015036-08; NCGC00015036-09; NCGC00015036-11; NCGC00015036-13; NCGC00015036-24; NCGC00162039-01; NCGC00162039-02; NCGC00162039-03; NCGC00162039-04; NCGC00179597-01; AC-25879; ADS-5102, EXP 105-1; AK-77141; AS-14215; BP-13040; K333; ST097860; SBI-0049993.P004; AB0014168; WLN: L66 B6 A B- C 1B ITJ BZ; AB00514655; FT-0607338; C06818; D07441; M-4039; AB00053414-14; AB00053414-16; AB00053414_17; AB00053414_18; AB01275427-01; 768A945; A838887; AE-641/01634060; L000868; Q409761; J-650234; W-104338; BRD-K70330367-003-01-2; BRD-K70330367-003-03-8; Q27453436; F0001-1962
    Click to Show/Hide
Molecular Type
Small molecule
Disease Influenza [ICD-11: 1E30] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H17N
PubChem CID
2130
Canonical SMILES
C1C2CC3CC1CC(C2)(C3)N
InChI
1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
InChIKey
DKNWSYNQZKUICI-UHFFFAOYSA-N
CAS Number
CAS 768-94-5
ChEBI ID
CHEBI:2618
TTD Drug ID
D02KRS
DrugBank ID
DB00915
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ursodeoxycholic acid      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Activity STAT1  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The inhibition of viral gene replication was enhanced by the combination of triple combination of amantadine, ursodeoxycholic acidbip, and henyl dimethyl dicarboxylate.
Target and Pathway
Target(s) Influenza M2 protein (Influ M)  Molecule Info  [3]
WikiPathways Influenza Life Cycle Click to Show/Hide
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4128).
Reference 2 The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells. Arch Pharm Res. 2005 Apr;28(4):451-7.
Reference 3 Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76.
 Download Picture         KEGG Link